USFDA Issues Warning Letter to Clinical Investigator Linked to Alembic Bioequivalence Study
New Delhi: Alembic Pharmaceuticals Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) has issued a Warning Letter, dated July 10, 2026, to the Clinical Investigator associated with a bioequivalence study conducted at the company's Bioequivalence Facility in Vadodara.
The company clarified that the observations relate to the Informed Consent Form (ICF) used during the study and do not concern data integrity or restrict the operations of its Bioequivalence Facility.
The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
According to the company, the USFDA inspected its Bioequivalence Facility from March 3 to March 7, 2025, following which Alembic had disclosed the completion of the inspection to the stock exchanges on March 7, 2025. The latest regulatory communication relates to a subsequent Warning Letter issued to the Clinical Investigator involved in one of the bioequivalence studies conducted at the facility.
The company said the Warning Letter pertains to observations regarding the informed consent process, specifically the Informed Consent Form (ICF), and does not involve concerns related to data integrity.
Alembic further stated that it became aware of the Warning Letter on July 12, 2026. Based on its preliminary assessment, the company said the regulatory action does not impose any restrictions on the operations of its Bioequivalence Facility and is not expected to have any material financial impact at this stage.
The company added that it is evaluating the matter and is coordinating with the Clinical Investigator to submit an appropriate response to the USFDA within the prescribed timeline.
In its stock exchange filing, Alembic reiterated that the regulatory action is limited to observations concerning the informed consent process in the bioequivalence study and that it continues to assess the matter while working with the Clinical Investigator on the regulatory response.
